Filing Details
LIGAND PHARMACEUTICALS INC (NASDAQ:LGND) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event.
8k filedNASDAQ:LGND
LIGAND PHARMACEUTICALS INC (LGND) Reports Material Event to SEC
Filing Details LIGAND PHARMACEUTICALS INC (NASDAQ:LGND) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event. Market Context…
Market Context
LIGAND PHARMACEUTICALS INC's stock currently trades at $300.97 with a market capitalization of $3.6B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for LIGAND PHARMACEUTICALS INC's stock.
All SEC filings for LIGAND PHARMACEUTICALS INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View LGND Stock Page
Frequently Asked Questions
Where can I read LGND's SEC filings?
Browse all filings on our LGND SEC filings page.
What types of SEC filings does LIGAND PHARMACEUTICALS INC file?
Public companies like LIGAND PHARMACEUTICALS INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.